♥

Lupin Limited

ISIN : INE326A01037
NSE : LUPIN
BSE : 500257
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 41.87
EPS (TTM) : 49.51
Price to Earning (P/E) : 48.43
Book Value : 311.08
Price to Bookvalue (P/B) : 6.52
Dividend Yield : 0 %
Return on Equity (ROE) : 14.61 %
Return on Capital Employed (ROCE) : 16.24 %

Lupin Limited share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	2271.95 - 2276.8 0.2 %
Low / High	2171.95 - 2285.3 5.2 %
Trade Volume	20,977
52 Week Low / High	1838.65 - 2376 29.2 %

YOU MAY ALSO LIKE

Stock market course tutorial
Stock Market Investment Course explained in simple words.
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Share Market basics for beginners
Share Market jargons in simple terms

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR LUPIN LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	38830.3	37438.4	41455.2	43222.2	44300.8	48140.6	50385.6	51974.1	49607.9	56003.3
Total Income	39400.8	38177.8	41604.6	43401.8	44673.5	48368.9	50789.6	52427.6	49901.3	56681.1
Total Expenditure	36565.8	35799	36925.3	37895.5	38523.1	39577.7	41208	41754.5	39640.3	43593.6
Other Income	570.5	739.4	149.4	179.6	372.7	228.3	404	453.5	293.4	677.8
Operating Profit	2835	2378.8	4679.3	5506.3	6150.4	8791.2	9581.6	10673.1	10261	13087.5
Interest	414.7	427.8	548.8	840.9	925.5	856.7	806.4	740.1	712.9	680.1
PBDT	2420.3	1951	4130.5	4665.4	5224.9	7934.5	8775.2	9933	9548.1	12407.4
Depreciation	3271.9	1928.3	2034.7	2204	2639.9	2346.6	2478.5	2572	4571	2477.1
Profit Before Tax	-851.6	22.7	2095.8	2461.4	2585	5587.9	6296.7	7361	4977.1	9930.3
Tax	4267.3	890.9	751.1	884.9	161.1	1054.6	1343.5	1174	1294.9	1874.9
Profit After Tax	-5118.9	-868.2	1344.7	1576.5	2423.9	4533.3	4953.2	6187	3682.2	8055.4
Net Profit	-5118.9	-868.2	1344.7	1576.5	2423.9	4533.3	4953.2	6187	3682.2	8055.4
Equity Capital	909	909.3	909.4	909.6	910	910.2	910.5	910.7	911.4	911.9
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	-11.4	-1.96	2.85	3.37	5.19	9.94	10.76	13.46	7.89	17.57
Diluted Eps After Extraordinary Items	-11.4	-1.96	2.85	3.36	5.16	9.9	10.72	13.41	7.86	17.52
Diluted Eps Before Extraordinary Items	-11.4	-1.96	2.85	3.36	5.16	9.9	10.72	13.41	7.86	17.52

STANDALONE QUARTERLY RESULT FOR LUPIN LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	28553.9	27324.9	28289.6	28611.1	28362.7	34956.4	36592.3	41157.5	33958.8	41676.3
Total Income	29124.2	28178	28443.3	28782.1	28915.7	35233.8	36848.3	41389.1	34272.2	42067.1
Total Expenditure	23952.7	25226.2	25153	26459.8	25740.9	27906.2	28239.9	28984.1	26955.3	29688.2
Other Income	570.3	853.1	153.7	171	553	277.4	256	231.6	313.4	390.8
Operating Profit	5171.5	2951.8	3290.3	2322.3	3174.8	7327.6	8608.4	12405	7316.9	12378.9
Interest	245.8	198.7	183.8	307.5	294.4	161.8	153.2	113.6	134.9	135.5
PBDT	4925.7	2753.1	3106.5	2014.8	2880.4	7165.8	8455.2	12291.4	7182	12243.4
Depreciation	1310.2	1303.5	1377.6	1340.3	1462	1400.5	1494.8	1451.8	2900.4	1414.2
Profit Before Tax	3615.5	1449.6	1728.9	674.5	1418.4	5765.3	6960.4	10839.6	4281.6	10829.2
Tax	3974.4	277.8	242.7	270.5	228.3	995.7	1474.3	1675.2	440.8	1937.4
Profit After Tax	-358.9	1171.8	1486.2	404	1190.1	4769.6	5486.1	9164.4	3840.8	8891.8
Net Profit	-358.9	1171.8	1486.2	404	1190.1	4769.6	5486.1	9164.4	3840.8	8891.8
Equity Capital	909	909.3	909.4	909.6	910	910.2	910.5	910.7	911.4	911.9
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	-0.79	2.58	3.27	0.89	2.62	10.48	12.05	20.13	8.43	19.5
Diluted Eps After Extraordinary Items	-0.79	2.57	3.26	0.87	2.59	10.44	12.01	20.05	8.4	19.44
Diluted Eps Before Extraordinary Items	-0.79	2.57	3.26	0.87	2.59	10.44	12.01	20.05	8.4	19.44

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR LUPIN LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	164055	166417	200108
Total Income	166156	167150	201415
Total Expenditure	161867	148435	162108
Other Income	2100.9	733.6	1306.8
Operating Profit	4289.1	18714.8	39306.9
Interest	1427.7	2743	3116.1
PBDT	2861.4	15971.8	36190.8
Depreciation	16587.1	8806.9	11968.1
Profit Before Tax	-13725.7	7164.9	24222.7
Tax	1371.5	2688	4867
Profit After Tax	-15097.2	4476.9	19355.7
Net Profit	-15097.2	4476.9	19355.7
Equity Capital	909	910	911.4
Face Value (IN RS)	2	2	2
Reserves	120624	123735	141992
Calculated EPS	-33.62	9.45	42.01
Diluted Eps After Extraordinary Items	-33.65	9.41	41.87
Diluted Eps Before Extraordinary Items	-33.65	9.41	41.87

STANDALONE ANNUAL RESULT FOR LUPIN LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	117717	112588	146665
Total Income	119887	113501	147732
Total Expenditure	115625	101762	112074
Other Income	2169.9	912.6	1067.3
Operating Profit	4261.3	11739.2	35657.9
Interest	734.7	984.4	563.5
PBDT	3526.6	10754.8	35094.4
Depreciation	5141.9	5483.4	7247.5
Profit Before Tax	-1615.3	5271.4	27846.9
Tax	271.7	1019.3	4586
Profit After Tax	-1887	4252.1	23260.9
Net Profit	-1887	4252.1	23260.9
Equity Capital	909	910	911.4
Face Value (IN RS)	2	2	2
Reserves	180593	183209	205120
Calculated EPS	-4.15	9.35	51.04
Diluted Eps After Extraordinary Items	-4.16	9.31	50.87
Diluted Eps Before Extraordinary Items	-4.16	9.31	50.87

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR LUPIN LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	28262.5 Cr	30300.1 Cr	28445.9 Cr	31737.5 Cr
Sales	28013.4 Cr	29701.6 Cr	28017.5 Cr	31065.9 Cr
Processing Charges / Service Income	13.09 Cr	385.81 Cr	56.72 Cr	317.15 Cr
Net Sales	15163 Cr	16405.5 Cr	16641.7 Cr	20010.8 Cr
Increase/Decrease in Stock	-484.86 Cr	-198.32 Cr	153.73 Cr	-457.44 Cr
Raw Material Consumed	5339.14 Cr	5979.16 Cr	5870.16 Cr	6102.1 Cr
Opening Raw Materials	805.14 Cr	900.39 Cr	1075.03 Cr	1000.22 Cr
Purchases Raw Materials	2757.08 Cr	2709.95 Cr	2857.13 Cr	3079 Cr
Closing Raw Materials	900.39 Cr	1075.03 Cr	1000.22 Cr	935.84 Cr
Other Direct Purchases / Brought in cost	2677.31 Cr	3443.85 Cr	2938.22 Cr	2958.72 Cr
Power & Fuel Cost	414.48 Cr	443.96 Cr	479.68 Cr	493.07 Cr
Electricity & Power	414.48 Cr	443.96 Cr	479.68 Cr	493.07 Cr
Employee Cost	2825.9 Cr	2989.3 Cr	3087.15 Cr	3494.57 Cr
Salaries, Wages & Bonus	2443.98 Cr	2583.52 Cr	2660.18 Cr	2959.66 Cr
Contributions to EPF & Pension Funds	200.98 Cr	211.61 Cr	227.85 Cr	265.47 Cr
Workmen and Staff Welfare Expenses	112.86 Cr	117.5 Cr	121.92 Cr	136.21 Cr
Other Manufacturing Expenses	1945.67 Cr	2187.99 Cr	2176.13 Cr	2738.39 Cr
Sub-contracted / Out sourced services	163.35 Cr	150.51 Cr	159.83 Cr	190.25 Cr
Processing Charges	135.09 Cr	128.95 Cr	175.63 Cr	254.02 Cr
Repairs and Maintenance	382.26 Cr	418.83 Cr	452.39 Cr	468.17 Cr
Packing Material Consumed	507.96 Cr	700.4 Cr	755.87 Cr	998.81 Cr
General and Administration Expenses	1218.42 Cr	3490.62 Cr	1733.07 Cr	2221.17 Cr
Rent , Rates & Taxes	199.01 Cr	247.6 Cr	237.01 Cr	251.58 Cr
Insurance	93.28 Cr	95.09 Cr	105.45 Cr	116.72 Cr
Professional and legal fees	712.05 Cr	761.24 Cr	899.27 Cr	1225.97 Cr
Traveling and conveyance	127.16 Cr	231.2 Cr	280.86 Cr	368.63 Cr
Selling and Distribution Expenses	1026.4 Cr	1096.1 Cr	1188.72 Cr	1343.3 Cr
Advertisement & Sales Promotion	667.14 Cr	711.7 Cr	768.22 Cr	903.86 Cr
Sales Commissions & Incentives	117.29 Cr	114.91 Cr	113.59 Cr	127.28 Cr
Freight and Forwarding	241.97 Cr	269.49 Cr	306.91 Cr	312.16 Cr
Miscellaneous Expenses	310.93 Cr	201.43 Cr	232.45 Cr	286.55 Cr
Bad debts /advances written off	42.69 Cr	4.62 Cr	3.43 Cr	19 Lk
Provision for doubtful debts	18.81 Cr	0	11.72 Cr	65.35 Cr
Loss on disposal of fixed assets(net)	0	2.93 Cr	0	0
Loss on foreign exchange fluctuations	90.93 Cr	0	0	0
Loss on sale of non-trade current investments	0	0	0	10.9 Cr
Total Expenditure	12596.1 Cr	16190.2 Cr	14921.1 Cr	16221.7 Cr
Other Income	136.29 Cr	213.67 Cr	150.91 Cr	141.58 Cr
Interest Received	39.69 Cr	96 Cr	32.43 Cr	46.23 Cr
Profit on sale of Fixed Assets	93 Lk	0	20.98 Cr	0
Profits on sale of Investments	0	26 Lk	36 Lk	1.17 Cr
Provision Written Back	87 Lk	3.58 Cr	19 Lk	6 Lk
Foreign Exchange Gains	0	68.4 Cr	77.55 Cr	10.51 Cr
Operating Profit	2703.17 Cr	428.91 Cr	1871.48 Cr	3930.69 Cr
Interest	140.64 Cr	142.77 Cr	274.3 Cr	311.61 Cr
Bank Charges etc	23.16 Cr	35.51 Cr	34.09 Cr	32.57 Cr
PBDT	2562.53 Cr	286.14 Cr	1597.18 Cr	3619.08 Cr
Depreciation	887.41 Cr	1658.71 Cr	880.69 Cr	1196.81 Cr
Profit Before Taxation & Exceptional Items	1675.12 Cr	-1372.57 Cr	716.49 Cr	2422.27 Cr
Profit Before Tax	1675.12 Cr	-1372.57 Cr	716.49 Cr	2422.27 Cr
Provision for Tax	448.52 Cr	137.15 Cr	268.8 Cr	486.7 Cr
Current Income Tax	441.67 Cr	139.15 Cr	246.25 Cr	634.36 Cr
Deferred Tax	10.05 Cr	-24 Cr	22.38 Cr	-147.15 Cr
Profit After Tax	1226.6 Cr	-1509.72 Cr	447.69 Cr	1935.57 Cr
Minority Interest	0	-18.68 Cr	-17.61 Cr	-21.09 Cr
Share of Associate	-10.07 Cr	36 Lk	0	0
Consolidated Net Profit	1216.53 Cr	-1528.04 Cr	430.08 Cr	1914.48 Cr
Profit Balance B/F	10229.6 Cr	11108.3 Cr	9288.42 Cr	9535.95 Cr
Appropriations	11446.2 Cr	9580.28 Cr	9718.5 Cr	11450.4 Cr
Other Appropriation	271.88 Cr	291.86 Cr	182.55 Cr	267.06 Cr
Equity Dividend %	325	200	200	400
Earnings Per Share	26.81	-33.62	9.45	42.01
Adjusted EPS	26.81	-33.62	9.45	42.01

STANDALONE PROFIT / LOSS FOR LUPIN LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	11896.3 Cr	12828.3 Cr	11319.3 Cr	14733.6 Cr
Sales	11714 Cr	11748 Cr	10840.3 Cr	14020.3 Cr
Processing Charges / Service Income	27.35 Cr	567.02 Cr	263.29 Cr	363.32 Cr
Net Sales	11055.9 Cr	11771.7 Cr	11258.8 Cr	14666.5 Cr
Increase/Decrease in Stock	-81.86 Cr	-242.38 Cr	120.79 Cr	-15.93 Cr
Raw Material Consumed	3851.37 Cr	4110.54 Cr	4079.64 Cr	4227.36 Cr
Opening Raw Materials	679.1 Cr	760.15 Cr	887.89 Cr	855.61 Cr
Purchases Raw Materials	2409.47 Cr	2345.54 Cr	2521.66 Cr	2535.8 Cr
Closing Raw Materials	760.15 Cr	887.89 Cr	855.61 Cr	797.91 Cr
Other Direct Purchases / Brought in cost	1522.95 Cr	1892.74 Cr	1525.7 Cr	1633.86 Cr
Power & Fuel Cost	389.54 Cr	418.45 Cr	447.42 Cr	444.41 Cr
Electricity & Power	389.54 Cr	418.45 Cr	447.42 Cr	444.41 Cr
Employee Cost	1695.86 Cr	1918.16 Cr	1934.14 Cr	2095.51 Cr
Salaries, Wages & Bonus	1450.56 Cr	1646.58 Cr	1670.16 Cr	1773.43 Cr
Contributions to EPF & Pension Funds	122.71 Cr	133.09 Cr	140.42 Cr	152.69 Cr
Workmen and Staff Welfare Expenses	72.14 Cr	80.13 Cr	72.28 Cr	72 Cr
Other Manufacturing Expenses	1548.59 Cr	1808.19 Cr	1752.86 Cr	1996.32 Cr
Sub-contracted / Out sourced services	120.37 Cr	120.08 Cr	114.58 Cr	127.54 Cr
Processing Charges	83.93 Cr	77.77 Cr	74.61 Cr	71.93 Cr
Repairs and Maintenance	292.91 Cr	333.17 Cr	351.47 Cr	357.98 Cr
Packing Material Consumed	412.8 Cr	599.1 Cr	597.26 Cr	813.8 Cr
General and Administration Expenses	958.16 Cr	2951.8 Cr	1238.62 Cr	1574.83 Cr
Rent , Rates & Taxes	150.56 Cr	195.47 Cr	179.31 Cr	167.87 Cr
Insurance	69.1 Cr	67.53 Cr	72.82 Cr	76.74 Cr
Professional and legal fees	567.35 Cr	579.18 Cr	705.33 Cr	992.5 Cr
Traveling and conveyance	114.63 Cr	204.98 Cr	226.32 Cr	305.83 Cr
Selling and Distribution Expenses	423.41 Cr	497.52 Cr	582.41 Cr	693.16 Cr
Advertisement & Sales Promotion	248.47 Cr	304.48 Cr	386.03 Cr	483.71 Cr
Sales Commissions & Incentives	94.63 Cr	108.21 Cr	112.51 Cr	126.44 Cr
Freight and Forwarding	80.31 Cr	84.83 Cr	83.87 Cr	83.01 Cr
Miscellaneous Expenses	226.8 Cr	104.41 Cr	139.05 Cr	211.46 Cr
Bad debts /advances written off	1 Lk	0	68 Lk	2 Lk
Provision for doubtful debts	17.12 Cr	1.15 Cr	10.68 Cr	16.85 Cr
Loss on disposal of fixed assets(net)	7 Lk	2.32 Cr	0	24 Lk
Loss on foreign exchange fluctuations	92.5 Cr	0	0	0
Loss on sale of non-trade current investments	0	0	0	10.9 Cr
Total Expenditure	9011.87 Cr	11566.7 Cr	10294.9 Cr	11227.1 Cr
Other Income	129.09 Cr	221.15 Cr	210.02 Cr	126.41 Cr
Interest Received	31.75 Cr	86.3 Cr	7.11 Cr	16.16 Cr
Profits on sale of Investments	2 Cr	9.87 Cr	41.1 Cr	64 Lk
Foreign Exchange Gains	0	66.57 Cr	118.76 Cr	8.78 Cr
Operating Profit	2173.15 Cr	426.13 Cr	1173.92 Cr	3565.79 Cr
Interest	40.62 Cr	73.47 Cr	98.44 Cr	56.35 Cr
Bank Charges etc	2.45 Cr	12.65 Cr	13.04 Cr	13.99 Cr
PBDT	2132.53 Cr	352.66 Cr	1075.48 Cr	3509.44 Cr
Depreciation	502.83 Cr	514.19 Cr	548.34 Cr	724.75 Cr
Profit Before Taxation & Exceptional Items	1629.7 Cr	-161.53 Cr	527.14 Cr	2784.69 Cr
Profit Before Tax	1629.7 Cr	-161.53 Cr	527.14 Cr	2784.69 Cr
Provision for Tax	371.08 Cr	27.17 Cr	101.93 Cr	458.6 Cr
Current Income Tax	367.1 Cr	39.49 Cr	93.7 Cr	487.3 Cr
Deferred Tax	8.23 Cr	-30.63 Cr	6.04 Cr	-25.45 Cr
Profit After Tax	1258.62 Cr	-188.7 Cr	425.21 Cr	2326.09 Cr
Consolidated Net Profit	1258.62 Cr	-188.7 Cr	425.21 Cr	2326.09 Cr
Profit Balance B/F	14592.9 Cr	15514.1 Cr	15032.7 Cr	15274.7 Cr
Appropriations	15851.6 Cr	15325.4 Cr	15458 Cr	17600.8 Cr
Other Appropriation	271.88 Cr	292.66 Cr	183.24 Cr	266.83 Cr
Equity Dividend %	325	200	200	400
Earnings Per Share	27.74	-4.15	9.35	51.04
Adjusted EPS	27.74	-4.15	9.35	51.04

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR LUPIN LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	1676.45 Cr	-1372.21 Cr	716.49 Cr	2422.27 Cr
Adjustment	1053.31 Cr	1707.68 Cr	1097.41 Cr	1466.63 Cr
Changes In working Capital	-192.49 Cr	-15.04 Cr	326.52 Cr	85.51 Cr
Cash Flow after changes in Working Capital	2537.27 Cr	320.43 Cr	2140.42 Cr	3974.41 Cr
Cash Flow from Operating Activities	1821.76 Cr	367.31 Cr	1897.24 Cr	3648.36 Cr
Cash Flow from Investing Activities	-1239.58 Cr	1292.23 Cr	-1286.77 Cr	-1712.2 Cr
Cash Flow from Financing Activitie	-1885.27 Cr	-1572.32 Cr	-337.25 Cr	-2184.21 Cr
Net Cash Inflow / Outflow	-1303.09 Cr	87.22 Cr	273.22 Cr	-248.05 Cr
Opening Cash & Cash Equivalents	2229.31 Cr	926.22 Cr	991.37 Cr	1231.81 Cr
Closing Cash & Cash Equivalent	926.22 Cr	1013.44 Cr	1264.59 Cr	983.76 Cr

STANDALONE CASH FLOW FOR LUPIN LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	1629.7 Cr	-161.53 Cr	527.14 Cr	2784.69 Cr
Adjustment	507.21 Cr	449.36 Cr	583.79 Cr	771.3 Cr
Changes In working Capital	-118.04 Cr	-284.97 Cr	809.86 Cr	-905.21 Cr
Cash Flow after changes in Working Capital	2018.87 Cr	2.86 Cr	1920.79 Cr	2650.78 Cr
Cash Flow from Operating Activities	1570.08 Cr	151.03 Cr	1793.99 Cr	2504.13 Cr
Cash Flow from Investing Activities	-2507.52 Cr	-371.79 Cr	-1269.17 Cr	-1599.02 Cr
Cash Flow from Financing Activitie	-53.17 Cr	102.45 Cr	-498.26 Cr	-867.07 Cr
Net Cash Inflow / Outflow	-990.61 Cr	-118.31 Cr	26.56 Cr	38.04 Cr
Opening Cash & Cash Equivalents	1168.02 Cr	177.41 Cr	59.1 Cr	85.66 Cr
Closing Cash & Cash Equivalent	177.41 Cr	59.1 Cr	85.66 Cr	123.7 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR LUPIN LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	90.74 Cr	90.9 Cr	91 Cr	91.14 Cr
Equity - Authorised	200 Cr	200 Cr	200 Cr	200 Cr
Equity - Issued	90.74 Cr	90.9 Cr	91 Cr	91.14 Cr
Equity Paid Up	90.74 Cr	90.9 Cr	91 Cr	91.14 Cr
Face Value	2	2	2	2
Total Reserves	13522.9 Cr	11900.6 Cr	12224.6 Cr	14084.7 Cr
Securities Premium	988.71 Cr	1062.04 Cr	1107.58 Cr	1179.36 Cr
Capital Reserves	26.39 Cr	26.39 Cr	26.39 Cr	26.39 Cr
Profit & Loss Account Balance	11174.3 Cr	9288.42 Cr	9535.95 Cr	11183.4 Cr
General Reserves	1691.68 Cr	1713.41 Cr	1723.26 Cr	1738.7 Cr
Reserve excluding Revaluation Reserve	13522.9 Cr	11900.6 Cr	12224.6 Cr	14084.7 Cr
Shareholder's Funds	13803.1 Cr	12153.3 Cr	12464.5 Cr	14290.3 Cr
Minority Interest	54.97 Cr	68.71 Cr	78.32 Cr	83.16 Cr
Secured Loans	33 Lk	141.86 Cr	0	0
Term Loans - Banks	33 Lk	141.86 Cr	0	0
Unsecured Loans	15.79 Cr	0	27.51 Cr	0
Long Term Loan in Foreign Currency	0	0	27.51 Cr	0
Loans - Banks	15.64 Cr	0	0	0
Deferred Tax Assets / Liabilities	49.56 Cr	71.1 Cr	73.78 Cr	-56.66 Cr
Deferred Tax Assets	325.37 Cr	266.6 Cr	269.47 Cr	481.1 Cr
Deferred Tax Liability	374.93 Cr	337.7 Cr	343.25 Cr	424.44 Cr
Other Long Term Liabilities	740.86 Cr	607.12 Cr	547.77 Cr	500.96 Cr
Long Term Provisions	329.49 Cr	332.99 Cr	343.03 Cr	375.4 Cr
Total Non-Current Liabilities	1136.03 Cr	1153.07 Cr	992.09 Cr	819.7 Cr
Trade Payables	2014.44 Cr	2282.91 Cr	2531.53 Cr	2958.11 Cr
Sundry Creditors	1974.73 Cr	2223.76 Cr	2459.51 Cr	2958.11 Cr
Acceptances	39.71 Cr	59.15 Cr	72.02 Cr	0
Other Current Liabilities	2451.01 Cr	1394.11 Cr	1577.22 Cr	1919.4 Cr
Advances received from customers	26.07 Cr	15.59 Cr	15.25 Cr	24.99 Cr
Interest Accrued But Not Due	4.86 Cr	0	0	0
Short Term Borrowings	3049.44 Cr	3702.3 Cr	4216.54 Cr	2669.91 Cr
Secured ST Loans repayable on Demands	242.59 Cr	256.62 Cr	0	0
Working Capital Loans- Sec	242.59 Cr	256.62 Cr	0	0
Short Term Provisions	921.2 Cr	897.12 Cr	940.08 Cr	954.08 Cr
Provision for Tax	136.82 Cr	414.11 Cr	424.97 Cr	429.14 Cr
Provision for post retirement benefits	4.94 Cr	1.84 Cr	89 Lk	1.87 Cr
Total Current Liabilities	8436.09 Cr	8276.44 Cr	9265.37 Cr	8501.5 Cr
Total Liabilities	23430.2 Cr	21651.5 Cr	22800.3 Cr	23694.6 Cr
Gross Block	14726.8 Cr	15990.3 Cr	18077.4 Cr	19664.7 Cr
Less: Accumulated Depreciation	6845.99 Cr	7768.47 Cr	9698.33 Cr	10654 Cr
Less: Impairment of Assets	0	840.21 Cr	23.85 Cr	132.41 Cr
Net Block	7880.76 Cr	7381.62 Cr	8355.24 Cr	8878.3 Cr
Capital Work in Progress	851.54 Cr	847.47 Cr	894.82 Cr	595.67 Cr
Non Current Investments	78.07 Cr	77.6 Cr	77.13 Cr	227.7 Cr
Long Term Investment	78.07 Cr	77.6 Cr	77.13 Cr	227.7 Cr
Quoted	0	0	0	158.16 Cr
Unquoted	78.07 Cr	77.6 Cr	77.13 Cr	69.54 Cr
Long Term Loans & Advances	405.79 Cr	572.41 Cr	622.28 Cr	277.52 Cr
Other Non Current Assets	12.98 Cr	15.9 Cr	56.34 Cr	90.95 Cr
Total Non-Current Assets	9443.86 Cr	9193.81 Cr	10349 Cr	10247 Cr
Currents Investments	2376.81 Cr	822.4 Cr	439.77 Cr	846.93 Cr
Quoted	95.78 Cr	149.46 Cr	0	292.33 Cr
Unquoted	78.07 Cr	77.6 Cr	77.13 Cr	69.54 Cr
Inventories	4092.01 Cr	4630.73 Cr	4491.76 Cr	4953.9 Cr
Raw Materials	900.39 Cr	1075.03 Cr	1000.22 Cr	935.84 Cr
Work-in Progress	594.51 Cr	611.91 Cr	631.83 Cr	664.56 Cr
Finished Goods	745.59 Cr	788.81 Cr	738.93 Cr	936.7 Cr
Packing Materials	196.73 Cr	281.12 Cr	340.37 Cr	366 Cr
Stores and Spare	203.42 Cr	233.43 Cr	255.6 Cr	270.92 Cr
Sundry Debtors	4474.32 Cr	4261.94 Cr	4480.7 Cr	4692.05 Cr
Debtors more than Six months	0	369.44 Cr	113.03 Cr	126.34 Cr
Debtors Others	4538.4 Cr	3937.09 Cr	4416.75 Cr	4669.41 Cr
Cash and Bank	1742.46 Cr	1098.13 Cr	1293.13 Cr	1202.54 Cr
Cash in hand	1.16 Cr	1.1 Cr	1.17 Cr	1.6 Cr
Balances at Bank	1738.75 Cr	1094.95 Cr	1287.76 Cr	1181.59 Cr
Other Current Assets	556.89 Cr	532.02 Cr	668.44 Cr	1428.05 Cr
Prepaid Expenses	95.07 Cr	99.7 Cr	113.62 Cr	99.89 Cr
Short Term Loans and Advances	743.88 Cr	1112.46 Cr	1077.5 Cr	324.18 Cr
Advances recoverable in cash or in kind	211.03 Cr	219.58 Cr	197.43 Cr	266.39 Cr
Advance income tax and TDS	5.69 Cr	38.51 Cr	36.72 Cr	40.61 Cr
Total Current Assets	13986.4 Cr	12457.7 Cr	12451.3 Cr	13447.6 Cr
Net Current Assets (Including Current Investments)	5550.28 Cr	4181.24 Cr	3185.93 Cr	4946.15 Cr
Total Assets	23430.2 Cr	21651.5 Cr	22800.3 Cr	23694.6 Cr
Contingent Liabilities	419.62 Cr	668.79 Cr	800.63 Cr	860.7 Cr
Total Debt	4782.98 Cr	3844.16 Cr	4244.05 Cr	2669.91 Cr
Book Value	300.06	0	270.67	311.08
Adjusted Book Value	300.06	263.84	270.67	311.08

STANDALONE BALANCE SHEET FOR LUPIN LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	90.74 Cr	90.9 Cr	91 Cr	91.14 Cr
Equity - Authorised	200 Cr	200 Cr	200 Cr	200 Cr
Equity - Issued	90.74 Cr	90.9 Cr	91 Cr	91.14 Cr
Equity Paid Up	90.74 Cr	90.9 Cr	91 Cr	91.14 Cr
Face Value	2	2	2	2
Total Reserves	18285.3 Cr	17897.6 Cr	18172.5 Cr	20398.8 Cr
Securities Premium	988.72 Cr	1062.05 Cr	1107.58 Cr	1179.36 Cr
Capital Reserves	26.39 Cr	26.39 Cr	26.39 Cr	26.39 Cr
Profit & Loss Account Balance	15579.7 Cr	15032.7 Cr	15274.7 Cr	17334 Cr
General Reserves	1691.68 Cr	1713.41 Cr	1723.26 Cr	1738.7 Cr
Reserve excluding Revaluation Reserve	18285.3 Cr	17897.6 Cr	18172.5 Cr	20398.8 Cr
Shareholder's Funds	18565.6 Cr	18150.2 Cr	18411.9 Cr	20603.1 Cr
Unsecured Loans	15 Lk	0	0	0
Deferred Tax Assets / Liabilities	217.32 Cr	186.75 Cr	185.02 Cr	156.01 Cr
Deferred Tax Assets	173.01 Cr	166.33 Cr	187.25 Cr	224.38 Cr
Deferred Tax Liability	390.33 Cr	353.08 Cr	372.27 Cr	380.39 Cr
Other Long Term Liabilities	181.73 Cr	132.23 Cr	142.61 Cr	140.06 Cr
Long Term Provisions	307.96 Cr	306.29 Cr	316.33 Cr	329.76 Cr
Total Non-Current Liabilities	707.16 Cr	625.27 Cr	643.96 Cr	625.83 Cr
Trade Payables	1196.39 Cr	1351.53 Cr	1566.29 Cr	2036.27 Cr
Sundry Creditors	1156.68 Cr	1292.38 Cr	1494.27 Cr	2036.27 Cr
Acceptances	39.71 Cr	59.15 Cr	72.02 Cr	0
Other Current Liabilities	397.9 Cr	595.66 Cr	636.06 Cr	744.02 Cr
Advances received from customers	8.93 Cr	15.16 Cr	8.62 Cr	22.77 Cr
Short Term Borrowings	298.79 Cr	790.47 Cr	613.46 Cr	18.13 Cr
Secured ST Loans repayable on Demands	50.79 Cr	0	0	0
Working Capital Loans- Sec	50.79 Cr	0	0	0
Short Term Provisions	692.75 Cr	800.25 Cr	812.04 Cr	848 Cr
Provision for Tax	103.77 Cr	343.41 Cr	323.43 Cr	352.57 Cr
Total Current Liabilities	2585.83 Cr	3537.91 Cr	3627.85 Cr	3646.42 Cr
Total Liabilities	21858.6 Cr	22313.4 Cr	22683.7 Cr	24922.9 Cr
Gross Block	6230.28 Cr	6705.14 Cr	7408.43 Cr	7605.39 Cr
Less: Accumulated Depreciation	2591.45 Cr	3008.16 Cr	3375.03 Cr	3468.2 Cr
Less: Impairment of Assets	0	6.8 Cr	11.47 Cr	24.02 Cr
Net Block	3638.83 Cr	3690.18 Cr	4021.93 Cr	4113.17 Cr
Capital Work in Progress	795.83 Cr	773.74 Cr	737.99 Cr	411.12 Cr
Non Current Investments	7241.59 Cr	8688.69 Cr	9534.56 Cr	10771.8 Cr
Long Term Investment	7241.59 Cr	8688.69 Cr	9534.56 Cr	10771.8 Cr
Quoted	0	0	0	158.16 Cr
Unquoted	7241.59 Cr	8688.69 Cr	9534.56 Cr	10613.7 Cr
Long Term Loans & Advances	399.62 Cr	537.04 Cr	603.86 Cr	231.19 Cr
Other Non Current Assets	10.29 Cr	12.2 Cr	25.81 Cr	72.98 Cr
Total Non-Current Assets	12241.2 Cr	13875.6 Cr	15112.8 Cr	15635 Cr
Currents Investments	2320.99 Cr	822.4 Cr	439.77 Cr	808.85 Cr
Quoted	95.78 Cr	149.46 Cr	0	292.33 Cr
Unquoted	7241.59 Cr	8688.69 Cr	9534.56 Cr	10613.7 Cr
Inventories	2708.19 Cr	3177.14 Cr	3019.47 Cr	2969.31 Cr
Raw Materials	760.15 Cr	887.89 Cr	855.61 Cr	797.91 Cr
Work-in Progress	521.4 Cr	570.57 Cr	590.27 Cr	567.61 Cr
Finished Goods	608.88 Cr	660.58 Cr	607.85 Cr	687.66 Cr
Packing Materials	159.79 Cr	236.16 Cr	247.23 Cr	259.16 Cr
Stores and Spare	193 Cr	213.77 Cr	240.64 Cr	238.5 Cr
Sundry Debtors	3190.54 Cr	2722.01 Cr	2674.42 Cr	3842.15 Cr
Debtors more than Six months	0	56.91 Cr	197.81 Cr	100.16 Cr
Debtors Others	3213.17 Cr	2685.02 Cr	2501.47 Cr	3878.83 Cr
Cash and Bank	284.01 Cr	64.56 Cr	100.97 Cr	138.64 Cr
Cash in hand	68 Lk	67 Lk	75 Lk	83 Lk
Balances at Bank	280.78 Cr	63.06 Cr	97.46 Cr	130.72 Cr
Other Current Assets	490.58 Cr	673.29 Cr	1190.15 Cr	1157.87 Cr
Prepaid Expenses	35.59 Cr	39.39 Cr	39.24 Cr	34.52 Cr
Short Term Loans and Advances	623.06 Cr	978.42 Cr	146.14 Cr	223.36 Cr
Advances recoverable in cash or in kind	135.15 Cr	172.02 Cr	155.88 Cr	209.28 Cr
Total Current Assets	9617.37 Cr	8437.82 Cr	7570.92 Cr	9140.18 Cr
Net Current Assets (Including Current Investments)	7031.54 Cr	4899.91 Cr	3943.07 Cr	5493.76 Cr
Total Assets	21858.6 Cr	22313.4 Cr	22683.7 Cr	24922.9 Cr
Contingent Liabilities	4875.59 Cr	3595.95 Cr	3495.87 Cr	4029.78 Cr
Total Debt	299.1 Cr	790.47 Cr	613.46 Cr	18.13 Cr
Book Value	405.03	0	401.4	449.64
Adjusted Book Value	405.03	395.79	401.4	449.64

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR LUPIN LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	26.81	-33.62	9.45	42.01
CEPS(Rs)	46.59	3.28	29.2	68.74
DPS(Rs)	6.5	4	4	8
Book NAV/Share(Rs)	300.06	263.84	270.67	311.08
Tax Rate(%)	26.78	-9.99	37.52	20.09
Margin Ratios
Core EBITDA Margin(%)	9.08	0.71	6.05	11.94
EBIT Margin(%)	6.42	-4.06	3.48	8.61
Pre Tax Margin(%)	5.93	-4.53	2.52	7.63
PAT Margin (%)	4.34	-4.98	1.57	6.1
Cash Profit Margin (%)	7.48	0.49	4.67	9.87
Performance Ratios
ROA(%)	5.09	-6.7	2.01	8.33
ROE(%)	9.46	-11.79	3.68	14.61
ROCE(%)	9.7	-7.11	6.06	16.24
Asset Turnover(x)	1.17	1.34	1.28	1.37
Sales/Fixed Asset(x)	1.96	1.97	1.67	1.68
Working Capital/Sales(x)	5.09	7.25	8.93	6.42
Efficiency Ratios
Fixed Capital/Sales(x)	0.51	0.51	0.6	0.59
Receivable days	64.06	52.62	56.09	52.75
Inventory Days	48.75	52.54	58.53	54.32
Payable days	62.54	132.55	141.89	177.49
Valuation Parameters
PER(x)	38.08	0	68.54	38.51
PCE(x)	21.91	227.59	22.19	23.54
Price/Book(x)	3.4	2.83	2.39	5.2
Yield(%)	0.64	0.54	0.62	0.49
EV/Net Sales(x)	3.26	2.23	1.95	3.76
EV/Core EBITDA(x)	18.26	85.46	17.33	19.13
EV/EBIT(x)	27.18	-29.8	32.73	27.5
EV/CE(x)	2.11	1.69	1.42	4.43
M Cap / Sales	3.05	2.07	1.77	3.68
Growth Ratio
Net Sales Growth(%)	-9.94	8.19	1.44	20.25
Core EBITDA Growth(%)	-8.62	-84.13	336.33	110.03
EBIT Growth(%)	46.93	-167.73	180.59	175.93
PAT Growth(%)	548.12	-223.08	129.66	332.35
EPS Growth(%)	550.89	-225.39	128.12	344.46
Financial Stability Ratios
Total Debt/Equity(x)	0.35	0.32	0.34	0.19
Current Ratio(x)	1.66	1.51	1.34	1.58
Quick Ratio(x)	1.17	0.95	0.86	1
Interest Cover(x)	12.91	-8.61	3.61	8.77
Total Debt/Mcap(x)	0.1	0.11	0.14	0.04

FINANCIAL RATIOS (STANDALONE) FOR LUPIN LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	27.74	-4.15	9.35	51.04
CEPS(Rs)	38.82	7.16	21.4	66.95
DPS(Rs)	6.5	4	4	8
Book NAV/Share(Rs)	405.03	395.79	401.4	449.64
Tax Rate(%)	22.77	-16.82	19.34	16.47
Margin Ratios
Core EBITDA Margin(%)	17.18	1.6	8.52	23.34
EBIT Margin(%)	14.04	-0.69	5.53	19.28
Pre Tax Margin(%)	13.7	-1.26	4.66	18.9
PAT Margin (%)	10.58	-1.47	3.76	15.79
Cash Profit Margin (%)	14.81	2.54	8.6	20.71
Performance Ratios
ROA(%)	5.92	-0.85	1.89	9.77
ROE(%)	7.06	-1.04	2.35	12
ROCE(%)	9.19	-0.47	3.3	14.33
Asset Turnover(x)	0.56	0.58	0.5	0.62
Sales/Fixed Asset(x)	2	1.98	1.6	1.96
Working Capital/Sales(x)	1.69	2.62	2.87	2.68
Efficiency Ratios
Fixed Capital/Sales(x)	0.5	0.5	0.62	0.51
Receivable days	104.42	84.11	87.01	80.72
Inventory Days	79.66	83.73	99.91	74.18
Payable days	56.88	115.55	121.07	156.12
Valuation Parameters
PER(x)	36.8	0	69.32	31.7
PCE(x)	26.3	104.18	30.28	24.17
Price/Book(x)	2.52	1.88	1.61	3.6
Yield(%)	0.64	0.54	0.62	0.49
EV/Net Sales(x)	4.19	2.94	2.66	5.02
EV/Core EBITDA(x)	21.32	81.28	25.55	20.64
EV/EBIT(x)	27.74	-393.3	47.94	25.91
EV/CE(x)	2.12	1.55	1.32	3.57
M Cap / Sales	4.19	2.88	2.62	5.03
Growth Ratio
Net Sales Growth(%)	0.27	6.47	-4.36	30.27
Core EBITDA Growth(%)	-8.8	-80.39	175.48	203.75
EBIT Growth(%)	51.18	-105.27	810.4	354.15
PAT Growth(%)	72.99	-114.99	325.34	447.05
EPS Growth(%)	72.73	-114.97	325.09	446.2
Financial Stability Ratios
Total Debt/Equity(x)	0.02	0.04	0.03	0
Current Ratio(x)	3.72	2.38	2.09	2.51
Quick Ratio(x)	2.67	1.49	1.25	1.69
Interest Cover(x)	41.12	-1.2	6.35	50.42
Total Debt/Mcap(x)	0.01	0.02	0.02	0

SHARE HOLDING PATTERN FOR LUPIN LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	46.82	46.83	46.82	46.80	46.79	46.77	46.76	46.73	46.70	46.68
FII %	14.27	13.81	13.98	13.32	13.93	14.99	16.11	18.29	19.32	21.50
DII %	0.07	0.09	0.09	0.09	0.10	0.03	0.03	0.06	0.03	0.03
Public %	11.45	11.45	9.53	10.40	9.64	8.52	7.11	6.93	6.92	6.44

PEER COMPARISON FOR LUPIN LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR LUPIN LIMITED

Exchange Date	Purpose	Book Closure Dates
BSE 22-Oct-2024	Board Meeting - Quarterly Results	07-Nov-2024
BSE 23-Jul-2024	Board Meeting - Quarterly Results	06-Aug-2024
BSE 06-May-2024	Dividend - Rs.8.0000 per share(400%)Final Dividend
BSE 22-Apr-2024	Board Meeting - Final Dividend & Audited Results	06-May-2024
BSE 24-Jan-2024	Board Meeting - Quarterly Results	07-Feb-2024
BSE 22-Dec-2023	SAST - Lupin Atlantis Holdings SA, Switzerland, wholly owned subsidiary of Lupin Limited has signed an Asset Purchase Agreement with Sanofi, a French Multinational pharmaceutical and healthcare company, for acquiring a portfolio of accretive established products in Europe and Canada.
BSE 25-Oct-2023	Board Meeting - Quarterly Results	08-Nov-2023
BSE 22-Sep-2023	SAST - Lupin Acquires Five Brands from Menarini.
BSE 21-Jul-2023	Board Meeting - Quarterly Results	03-Aug-2023
BSE 20-Jul-2023	SAST - NCLT, Mumbai, has approved Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries of Aarogya Bharat Digital LLP, which in turn is a wholly owned subsidiary of ABCD Technologies LLP.
BSE 10-May-2023	Dividend - Rs.4.0000 per share (200%)Final Dividend
BSE 05-May-2023	SAST - Acquisition of French Pharmaceutical Company Medisol.
BSE 25-Apr-2023	Board Meeting - Audited Results & Final Dividend	09-May-2023
BSE 25-Jan-2023	Board Meeting - Quarterly Results	09-Feb-2023
BSE 27-Oct-2022	Board Meeting - Quarterly Results	09-Nov-2022
BSE 20-Jul-2022	Board Meeting - Quarterly Results	03-Aug-2022
BSE 18-May-2022	Dividend - Rs.4.0000 per share(200%)Final Dividend
BSE 04-May-2022	Board Meeting - Final Dividend & Audited Results	18-May-2022
BSE 19-Jan-2022	Board Meeting - Quarterly Results	03-Feb-2022
BSE 14-Oct-2021	Board Meeting - Quarterly Results	27-Oct-2021

CORPORATE ANNOUNCEMENTS FOR LUPIN LIMITED

Exchange Date	Category File	Description
BSE 24-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 23-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Intimation regarding allotment of 51609 shares under ESOP.
BSE 22-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Earnings Call for Q2 FY25 scheduled on Friday November 8 2024 at 16:00 hrs (IST).
BSE 22-Oct-2024	Intimation FILE	Board Meeting Intimation for Considering And Taking On Record The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2024 And Other Business Matters. LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2024.
BSE 21-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issuance of duplicate share certificates.
BSE 18-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Appointment of Senior Management Personnel by its wholly owned subsidiary.
BSE 16-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 15-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Lupin Launches First Generic of Pred Forte in the United States.
BSE 11-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 10-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issuance of duplicate share certificates.
BSE 09-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholders.
BSE 07-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended on September 30 2024.
BSE 05-Oct-2024	General Announcements FILE	U.S. FDA Inspection Of The Company'S Biotech Facility In Pune. U.S. FDA Inspection of the Companys Biotech Facility in Pune.
BSE 03-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 01-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 01-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 30-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 28-Sep-2024	General Announcements FILE	U.S. FDA Inspection Of The Company'S Manufacturing Facility At Pithampur Unit-1. U.S. FDA Inspection of the Companys Manufacturing Facility at Pithampur Unit-1.
BSE 26-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 25-Sep-2024	Intimation FILE	Closure of Trading Window Intimation of Trading Window Closure period.
BSE 25-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholder.
BSE 23-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholders.
BSE 20-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issuance of duplicate share certificates.
BSE 20-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholders.
BSE 20-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Intimation regarding allotment of 5893 shares under ESOP.
BSE 19-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholders.
BSE 18-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan a Novel Gastrointestinal Drug in India.
BSE 16-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificates by the shareholder.
BSE 13-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation about participating in the Analyst/Institutional Investors Meet.
BSE 12-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate by the Shareholders.

INSIDER TRADING FOR LUPIN LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 06-Sep-2021 06-Sep-2021	Sell Market	15,000 @ 0.00 (0.01 %)	Kamal K Sharma
BSE 03-Sep-2021 03-Sep-2021	Sell Gift	5,300 @ 0.00 (0.00 %)	Nilesh D Gupta
BSE 03-Sep-2021 03-Sep-2021	Buy Gift	2,650 @ 0.00 (0.00 %)	Neel Deshbandhu Gupta
BSE 03-Sep-2021 03-Sep-2021	Buy Gift	2,650 @ 0.00 (0.01 %)	Veda Nilesh Gupta

BULK BLOCK DEALS FOR LUPIN LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 25-Jan-2024	Sell BLOCK	747,956 @ 1449.20	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Buy BLOCK	747,956 @ 1449.20	SOCIETE GENERALE
BSE 25-Oct-2022	Sell BLOCK	213,033 @ 680.75	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 25-Oct-2022	Buy BLOCK	213,033 @ 680.75	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 17-Oct-2022	Sell BLOCK	334,753 @ 690.65	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 17-Oct-2022	Buy BLOCK	334,753 @ 690.65	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 11-Oct-2022	Sell BLOCK	245,503 @ 707.20	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 11-Oct-2022	Buy BLOCK	245,503 @ 707.20	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	166,988 @ 632.15	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	166,988 @ 632.15	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 01-Aug-2022	Sell BLOCK	241,514 @ 644.10	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 01-Aug-2022	Buy BLOCK	241,514 @ 644.10	ISHARES MSCI INDIA ETF
BSE 18-Jul-2022	Sell BLOCK	242,963 @ 640.85	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 18-Jul-2022	Buy BLOCK	242,963 @ 640.85	ISHARES MSCI INDIA ETF
BSE 04-May-2022	Buy BLOCK	262,960 @ 741.85	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	262,960 @ 741.85	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO
BSE 20-Oct-2021	Sell BLOCK	204,131 @ 938.40	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 20-Oct-2021	Buy BLOCK	204,131 @ 938.40	ISHARES MSCI EMERGING MARKETS ETF
BSE 11-Oct-2021	Sell BLOCK	204,132 @ 947.30	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 11-Oct-2021	Buy BLOCK	204,132 @ 947.30	ISHARES MSCI EMERGING MARKETS ETF
BSE 23-Sep-2021	Sell BLOCK	207,778 @ 940.00	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 23-Sep-2021	Buy BLOCK	207,778 @ 940.00	ISHARES MSCI EMERGING MARKETS ETF
BSE 16-Sep-2021	Sell BLOCK	1,265,614 @ 989.80	GOLDMAN SACHS ASSET MANAGEMENT LLC A/C GOLDMAN SACHS INDIA FUND LIMITED
BSE 16-Sep-2021	Buy BLOCK	1,265,614 @ 989.80	GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO

DIVIDEND BY LUPIN LIMITED

Ex Dividend Date	Dividend Type	Dividend
16-Jul-2024	DIVIDEND	8
14-Jul-2023	DIVIDEND	4
14-Jul-2022	DIVIDEND	4
27-Jul-2021	DIVIDEND	6.5

SPLIT / BONUS BY LUPIN LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Lupin Limited

Lupin Limited share price

CONSOLIDATED QUARTERLY RESULT FOR LUPIN LIMITED

STANDALONE QUARTERLY RESULT FOR LUPIN LIMITED

CONSOLIDATED ANNUAL RESULT FOR LUPIN LIMITED

STANDALONE ANNUAL RESULT FOR LUPIN LIMITED

CONSOLIDATED PROFIT / LOSS FOR LUPIN LIMITED

STANDALONE PROFIT / LOSS FOR LUPIN LIMITED

CONSOLIDATED CASH FLOW FOR LUPIN LIMITED

STANDALONE CASH FLOW FOR LUPIN LIMITED

CONSOLIDATED BALANCE SHEET FOR LUPIN LIMITED

STANDALONE BALANCE SHEET FOR LUPIN LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR LUPIN LIMITED

FINANCIAL RATIOS (STANDALONE) FOR LUPIN LIMITED

SHARE HOLDING PATTERN FOR LUPIN LIMITED

PEER COMPARISON FOR LUPIN LIMITED

CORPORATE ACTIONS FOR LUPIN LIMITED

CORPORATE ANNOUNCEMENTS FOR LUPIN LIMITED

INSIDER TRADING FOR LUPIN LIMITED

BULK BLOCK DEALS FOR LUPIN LIMITED

DIVIDEND BY LUPIN LIMITED

SPLIT / BONUS BY LUPIN LIMITED